COMPARATIVE EVALUATION OF ANTIDIABETIC ACTIVITY OF ETHANOLIC LEAVES EXTRACT OF CLEMATIS TRILOBA AND THEIR SMEDDS FORMULATION IN STREPTOZOTOCIN INDUCED DIABETIC RATS

Main Article Content

Vishal Ramesh Rasve
Anup Kumar Chakraborty
Sachin Kumar Jain
Sudha Vengurlekar

Keywords

antidiabetic, α-glucosidase, streptozotocin, SMEDDS, Clematis Triloba, α-Amylase

Abstract

Objectives: The present study aimed to evaluate and compare the antidiabetic activity of ethanolic leaves extract of Clematis triloba and their SMEDDS formulation with Glibenclamide (GL) by α-amylase, α-glucosidase enzyme inhibitory assay and streptozotocin induced diabetic rats.


Methods: Using the 3,5-dinitrosalicylic acid method and 4-Nitrophenyl--D-glucopyranoside, respectively, the α-amylase inhibition and α-glucosidase enzyme inhibitory activities of Clematis Triloba extracts were assessed. In several animal models, including hypoglycemic, oral glucose-loaded, and streptozotocin-induced diabetic rat models, the extract and SMEDDS formulation ability to reduce levels of blood glucose was investigated.


Results: The enzymes α-amylase and α-glucosidase were significantly inhibited by the clematis triloba ethanolic extract in a dose-dependent manner. When compared to an ethanolic extract, the SMEDDS formulation of clematis triloba showed greater antidiabetic efficacy.


Conclusion: The current research suggests that clematis triloba's ethanolic leaf extracts have in vitro and in-vivo anti-diabetic action. This study showed that these herbs have great therapeutic efficacy in treating diabetes mellitus and its accompanying problems, hence proving their traditional applications in Indian traditional medicine.

Abstract 362 | pdf Downloads 36

References

1. American Diabetes Association, 1998. Economic consequences of diabetes mellitus in the United States in Diabetes Care, 1997; 21: 296-309.
2. Hoppener JW and Lips CJ. Role of islet amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol, 2006; 38(5- 6): 726-36.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1- diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539-53.
4. King H, Aubert RE, Herman WH. Global burden of diabetes 1995–2025: prevalence, numerical estimates, and projection. Diabetes Care. 1998; 21:1414–1431.
5. Naggar E M, Antidiabetic effect of Cleome droserifolia Areial parts: Lipid peroxidation-induced oxidative stress in diabetic rats Acta Vet. Brno. 2004; 74: 347.
6. Eddouks M, Maghrani M. Phlorizin-like effect of Fraxinus excelsior in normal and diabetic rats. J Ethnopharmacol. 2004; 9:149-54.
7. World Health Organization on Diabetes mellitus” Technical reports series. WHO Geneva 1980. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complication. Geneva: WHO: 1999, pp 14-16.
8. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation (PDF). Geneva: World Health Organization. 2006. Pp 21.
9. Mohan V. Evaluation of Diabecon (D-400) as an antidiabetic agent - a doubleblind placebo - controlled trial in NIDDM patients with secondary failure to oral drugs. Indian J Clin Pract 1998;8(9):18-25.
10. Kesarwani K, Gupta R. Bioavailability enhancers of herbal origin: an overview. Asian Pac J Trop Biomed 2013;3(4):253-66.
11. Judy WV, Hari SP, Stogsdill WW, Judy JS, Naquib YMA, Passwater R. Antidia-betic activity of a standardized extract (Glucosol) from Lagerstroemia speciosa leaves in Type II diabetics: a dose-dependence study. J Ethnopharmacol 2003;87(1):115-7.
12. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58(3): 173-82.
13. Haritha B. A review of the evaluation of tablets. Formulation Sci Bioavailability 2017; 1:1-5.
14. Stegemanna S, Leveillerb F. When poor solubility becomes an issue: From early stage to proof of concept. Eur J Pharm Sci 2007; 31:249-61.
15. Hetal PT, Jagruti LD. Influence of excipients on drug absorption via modulation of intestinal transporters activity. Asian J Pharm 2015; 9:69-82.
16. Kunde SD, Bhilegaonkar SH, Godbole AM, Gajre P. Biopharmaceutical classification system: A brief account. Int J Sci Res Methodol 2015; 1:20-46.
17. Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 2013; 102:34-42.
18. Ghadi RR, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. Drug Deliv Transl Res 2017; 248:71-95.
19. Thakare P, Mogal V, Borase P, Dusane J, Kshirsagar S. A review on self-emulsified drug delivery system. J Pharm Biol Eval 2016; 3:140-53.
20. Mistry R, Sheth NS. Self-emulsifying drug delivery system. Int J Pharm Sci 2011; 3:23-8.
21. Martin A. Solubility and Distribution Phenomena. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkin; 2011.
22. Vishal Ramesh Rasve, Anup K. Chakraborty, Sachin Kumar Jain, Sudha Vengurlekar (2022), ‘Study of phytochemical profiling and in vitro studies on antioxidant properties of ethanolic extract of clematis triloba.’ European chemical bulletin. (Eur. Chem. Bull.) 2022, 11(12), 2658-2677.
23. Khandelwal KR Practical pharmacognosy technique and experiments. 23rd Ed. NiraliPrakashan; 2005.
24. Kokate CK. Practical pharmacognosy. 4th Ed. Vallabh Prakashan; 1994.
25. Sofowra, A. 1993. Medicinal Plants And traditional Medicine In Africa. Spectrum Books Ltd., Ibadan, Nigeria, pp. 191-289.
26. Trease, G.E., Evans, W.C. 1989. Pharmacognosy, 11th edn., Bailliere Tindall, London, pp. 45-50.
27. Harborne, J.B. 1973. Phytochemicals Methods. Chapman and Hall Ltd., London, pp. 49-188.
28. Harborne, J. B. (1984). Phenolic compounds. In Phytochemical methods (pp. 37-99). Springer, Dordrecht. DOI: 10.1007/978-94-009-5570-7_2.
29. Olufunmiso OO, Afolayan AJ. Phenolic content and antioxidant property of the bark extract of Ziziphus mucronate willd. Subsp. Mucronate willd, BMC Complement Alternative Medicine 2011; 11:130.https://doi.org/10.1186/1472-6882-11-130
30. OECD Health Effects Testing Guidelines, OECD/OCDE guideline for testing of chemicals acute oral toxicity – acute toxic class method 423, December 2001 page no. 223 and 234.
31. Organization for Economic Co-operation and Development. OECD Guideline for the testing of chemicals. Acute oral toxicity: up and down procedure (UDP). Accessed June 5, 2020. https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecdtg423.pdf.
32. Soheila Moein, Elham Pimoradloo, Mahmoodreza Moein, Mahmood Vessal. Evaluation of Antioxidant Potentials and -Amylase Inhibition of Different Fractions of Labiatae Plants Extracts: As a Model of Anti-diabetic Compounds Properties. BioMed Research International. 2017; https://doi.org/10.1155/2017/7319504.
33. Karthikeyan M, Balasubramanian T, Kumar P (2016) In-vivo Animal Models and In-vitro Techniques for Screening Anti-diabetic Activity. J Develop Drugs 5: 153. doi:10.4172/2329-6631.1000153.
34. Deeds M, Anderson J, Armstrong A, et al. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim. 2011; 45:131-140.
35. Furman BL. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015; 70:5.47.1-5.20.
36. Vital P, Larrieta E, Hiriart M. Sexual dimorphism in insulin sensitivity and susceptibility to develop diabetes in rats. J Endocrinol. 2006; 190:425-432.
37. Birru EM, Abdelwuhab M, Shewamene Z. Effect of hydroalcoholic leaves extract of Indigofera spicata Forssk. on blood glucose level of normal, glucose loaded and diabetic rodents. BMC Complement Alternat Med. 2015; 15:321.
38. Gayathri Nambirajana, Kaleshkumar Karunanidhib, Arun Ganesanb, Rajaram Rajendran, Ruckmani Kandasamyc, Abbirami Elangovana, Sivasudha Thilagara, Evaluation of antidiabetic activity of bud and flower of Avaram Senna (Cassia auriculata L.) In high fat diet and streptozotocin induced diabetic rats, Biomedicine & Pharmacotherapy 108 (2018) 1495–1506.DOI: 10.1016/j.biopha.2018.10.007.
39. Khalil, R. R., Mohammed, E. T., & Mustafa, Y. F. (2022). Evaluation of In vitro Antioxidant and Antidiabetic Properties of Cydonia Oblonga Seeds' Extracts. Journal of Medicinal and Chemical Sciences, 5(6), 1048-1058. doi: 10.26655/JMCHEMSCI.2022.6.18.
40. Khalid M, Alqarni MH, Alsayari A, Foudah AI, Aljarba TM, Mukim M, Alamri MA, Abullais SS, Wahab S. Anti-Diabetic Activity of Bioactive Compound Extracted from Spondias mangifera Fruit: In-Vitro and Molecular Docking Approaches. Plants (Basel). 2022 Feb 21;11(4):562.
41. Paun G, Neagu E, Albu C, Savin S, Radu GL. In Vitro Evaluation of Antidiabetic and Anti-Inflammatory Activities of Polyphenolic-Rich Extracts from Anchusa officinalis and Melilotus officinalis. ACS Omega. 2020 May 22;5(22):13014-13022. doi: 10.1021/acsomega.0c00929. PMID: 32548486; PMCID: PMC7288582.
42. Ardalani H, Hejazi Amiri F, Hadipanah A, Kongstad KT. Potential antidiabetic phytochemicals in plant roots: a review of in vivo studies. J Diabetes Metab Disord. 2021 Jul 12;20(2):1837-1854. doi: 10.1007/s40200-021-00853-9.
43. Benoite T, Vigasini N. Antioxidant and Anti-diabetic Activities of Ethanolic Extract of Hibiscus sabdariffa calyx and Stevia rebaudiana Leaf. Asian J Biol Life Sci. 2021;10(1):217-24.
44. Mahnashi, M.H., Alqahtani, Y.S., Alqarni, A.O. et al. Crude extract and isolated bioactive compounds from Notholirion thomsonianum (Royale) Stapf as multitargets anti-diabetic agents: in-vitro and molecular docking approaches. BMC Complement Med Ther 21, 270 (2021). https://doi.org/10.1186/s12906-021-03443-7.
45. Borkar Vijay S., Senthil Kumaran K., Senthil Kumar KL., Gangurde Hemant H., Chordiya Mayur A., antidiabetic activity and isolation of bioactive compounds from hydrolea zeylanica, Indonesian J.Pharm.Vol.26No.4:185-191 doi: 10.14499/indonesianjpharm26iss4pp185.
46. Kifle ZD, Enyew EF. Evaluation of In Vivo Antidiabetic, In Vitro α-Amylase Inhibitory, and In Vitro Antioxidant Activity of Leaves Crude Extract and Solvent Fractions of Bersama abyssinica Fresen (Melianthaceae). J Evid Based Integr Med. 2020 Jan-Dec; 25:2515690X20935827. doi: 10.1177/2515690X20935827.